The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II open-label study of abiraterone acetate (AA) plus low-dose prednisone (P) with or without exemestane (E) in postmenopausal women with ER+ metastatic breast cancer (MBC) progressing after letrozole or anastrozole therapy.
Joyce O'Shaughnessy
Consultant or Advisory Role - Johnson & Johnson
Margaret K. Yu
Employment or Leadership Position - Janssen Research Development
Jill Kearney
Employment or Leadership Position - Janssen research and development
Stock Ownership - Johnson & Johnson
Julie S. Larsen
Employment or Leadership Position - Janssen research and development
Stock Ownership - Janssen Pharmaceutical
Arturo Molina
Employment or Leadership Position - Janssen research and development
Stock Ownership - Johnson & Johnson
Stephen R. D. Johnston
No relevant relationships to disclose